medigraphic.com
ISSN 0035-0052 (Impreso)

2017, Número 6

Siguiente >>

Rev Mex Pediatr 2017; 84 (6)


Supervivencia en niños con leucemia; un gran reto para nuestra sociedad contemporánea

Rendón-Macías ME, Reyes-Zepeda NC

Idioma: Español
Referencias bibliográficas: 24
Paginas: 213-215
Archivo PDF: 148.88 Kb.


FRAGMENTO

Las complicaciones médicas evolucionan con el tiempo, muestra de ello es la atención a los problemas crónico-degenerativos y neoplásicos propios de este siglo. Un ejemplo claro son las leucemias infantiles. Como es bien sabido, éstas son las principales neoplasias en la edad pediátrica, pues constituyen entre 25 y 45% de los tipos de cáncer.
Sin duda, la historia del tratamiento de las leucemias en niños ha sido fascinante gracias a un cambio en su pronóstico, de ser una enfermedad altamente letal en los años 60, se ha logrado curar algunas variedades hasta en 100%. Sin embargo, esta historia dista de ser real en todo el mundo, puesto que aún en este siglo XXI hay regiones donde esta enfermedad continúa con altos porcentajes de mortalidad. A pesar de los anterior, el panorama mundial es alentador; informes recientes de diversas regiones del mundo notifican que la supervivencia de estos niños se ha incrementado.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Starý J, Hrušák O. Recent advances in the management of pediatric acute lymphoblastic leukemia. F1000Research. 2016; 5: 2635.

  2. Pérez-Saldivar ML, Fajardo-Gutiérrez A, Bernáldez-Ríos R, Martínez-Avalos A, Medina-Sanson A, Espinosa-Hernández L et al. Childhood acute leukemias are frequent in Mexico City: descriptive epidemiology. BMC Cancer. 2011; 11: 355.

  3. Wang L, Gomez SL, Yasui Y. Racial and ethnic differences in socioeconomic position and risk of childhood acute lymphoblastic leukemia. Am J Epidemiol. 2017; 185(12): 1263-1271.

  4. Hunger SP, Lu X, Devidas M, Camitta BM, Gaynon PS, Winick NJ et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children’s oncology group. J Clin Oncol. 2012; 30(14): 1663-1669.

  5. Bonaventure A, Harewood R, Stiller CA, Gatta G, Clavel J, Stefan DC et al. Worldwide comparison of survival from childhood leukaemia for 1995-2009, by subtype, age, and sex (CONCORD-2): a population-based study of individual data for 89,828 children from 198 registries in 53 countries. Lancet Haematol. 2017; 4(5): e202-e217. Available from: http://linkinghub.elsevier.com/retrieve/pii/S2352302617300522

  6. Yifru S, Muluye D. Childhood cancer in Gondar University Hospital, Northwest Ethiopia. BMC Res Notes. 2015; 8: 474. Available from: http://www.biomedcentral.com/1756-0500/8/474

  7. Jabeen K, Ashraf MS, Iftikhar S, Belgaumi AF. The impact of socioeconomic factors on the outcome of childhood acute lymphoblastic leukemia (ALL) treatment in a low/middle income country (LMIC). J Pediatr Hematol Oncol. 2016; 38(8): 587-596.

  8. Pui C-H, Pei D, Pappo AS, Howard SC, Cheng C, Sandlund JT et al. Treatment outcomes in black and white children with cancer: results from the SEER database and St Jude Children’s Research Hospital, 1992 Through 2007. J Clin Oncol. 2012; 30(16): 2005-2012.

  9. Jakab Z, Juhasz A, Nagy C, Schuler D, Garami M. Trends and territorial inequalities of incidence and survival of childhood leukaemia and their relations to socioeconomic status in Hungary, 1971-2015. Eur J Cancer Prev. 2017; 26: S183-190.

  10. Jiménez-Hernández E, Jaimes-Reyes EZ, Arellano-Galindo J, García-Jiménez X, Tiznado-García HM, Dueñas-González MT et al. Survival of mexican children with acute lymphoblastic leukaemia under treatment with the protocol from the dana-farber cancer institute 00-01. Bio Med Res Int. 2015; 2015: 576950.

  11. Carroll WL, Hunger SP. Therapies on the horizon for childhood acute lymphoblastic leukemia. Curr Opin Pediatr. 2016; 28(1):12-18.

  12. Navarrete M, Rossi E, Brivio E, Carrillo JM, Bonilla M, Vasquez R et al. Treatment of childhood acute lymphoblastic leukemia in central America: a lower-middle income countries experience. Pediatr Blood Cancer. 2014; 61(5): 803-809.

  13. Martín-Trejo JA, Núñez-Enríquez JC, Fajardo-Gutiérrez A, Medina-Sansón A, Flores-Lujano J, Jiménez-Hernández E et al. Early mortality in children with acute lymphoblastic leukemia in a developing country: the role of malnutrition at diagnosis. A multicenter cohort MIGICCL study. Leuk Lymphoma. 2017; 58(4): 898-908.

  14. Schultz KR, Pullen DJ, Sather HN, Shuster JJ, Devidas M, Borowitz MJ et al. Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children’s Cancer Group (CCG). Blood. 2006; 109(3): 926-935.

  15. Hunger SP. Integrated risk stratification using minimal residual disease and sentinel genetic alterations in pediatric acute lymphoblastic leukemia. J Clin Oncol 2017; JCO2017760504.

  16. Huynh V, Laetsch TW, Schore RJ, Gaynon P, O’Brien MM. Redefining treatment failure for pediatric acute leukemia in the era of minimal residual disease testing. Pediatr Hematol Oncol. 2017; 30: 1-14.

  17. Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014; 371(16): 1507-1517.

  18. Afzal S, Ethier MC, Dupuis LL, Tang L, Punnett AS, Richardson SE et al. Risk factors for infection-related outcomes during induction therapy for childhood acute lymphoblastic leukemia. Pediatr Infect Dis J. 2009; 28(12): 1064-1068.

  19. Inaba H, Pei D, Wolf J, Hayden RT, Go M, Varechtchouk O et al. Infection-related complications during treatment for childhood acute lymphoblastic leukemia. Ann Oncol. 2017; 28(2): 386-392.

  20. Keng MK, Sekeres MA. Febrile neutropenia in hematologic malignancies. Curr Hematol Malig Rep. 2013; 8(4): 370-378.

  21. Santiago R, Vairy S, Sinnett D, Krajinovic M, Bittencourt H. Novel therapy for childhood acute lymphoblastic leukemia. Expert Opin Pharmacother. 2017; 18(11): 1081-1099.

  22. Felice MS, Rossi JG, Alonso CN, Rubio P, Gallego MS, Galluzzo ML et al. Second neoplasms in children following a treatment for acute leukemia and/or lymphoma: 29 years of experience in a Single Institution in Argentina. J Pediatr Hematol Oncol. 2017; 39(8): e406-412.

  23. Bonilla M, Moreno N, Marina N, deReyes G, Shurtleff SA, Downing JR et al. Acute lymphoblastic leukemia in a developing country: preliminary results of a nonrandomized clinical trial in El Salvador. J Pediatr Hematol Oncol. 2000; 22(6): 495-501.

  24. Villasís-Keever MA, Rendón-Macías ME, Escamilla-Núñez A. Estándares para el otorgamiento óptimo de los cuidados que requieren los pacientes pediátricos con leucemia linfoblástica aguda y linfoma de Hodgkin. Bol Med Hosp Infant Mex. 2012; 69(3): 164-174.




2020     |     www.medigraphic.com